Paul Peter Tak

Company: Candel Therapeutics

Job title: President & Chief Executive Officer

Seminars:

Oncolytic Viral Immunotherapy For Hard-To-Treat Solid Tumors 3:00 pm

Introduction to oncolytic viral immunotherapy as a new approach to induce a specific immune response against the injected solid tumor and uninjected distant metastases Clinical and immunological data showing the effects of experimental treatment with CAN-2409 in combination with immune checkpoint inhibitors (ICI) in patients with stage III/IV NSCLC who had an inadequate response to…Read more

day: Day Two